VJHemOnc is committed to improving our service to you

EHA 2019 | Belantamab mafodotin for myeloma: Phase 1 data & patient-reported outcomes

VJHemOnc is committed to improving our service to you

Rakesh Popat

Rakesh Popat, MBBS, MRCP, FRCPath, PhD, University College London Hospitals NHS Foundation Trust, London, UK, discusses the data on the BCMA-directed antibody-drug conjugate belantamab mafodotin (GSK2857916) from the first-in-human Phase I trial (DREAMM-1; NCT02064387) and patient-reported outcomes. This interview took place at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter